Eyeworld

32 | EYEWORLD | JULY 2023 ASCRS NEWS Relevant disclosures Canabrava: None Ellis: JelliSee Ophthalmics Lewis: ViaLase Link: AEYE, Aurion Biotech, CorneaGen, LENSAR, Osanni Bio, RxSight, Surface Pharma, Tarsus Pharmaceuticals, TearClear, ViaLase Lobanoff: Phorcides Yeu: Carl Zeiss Meditec action. That was wonderful learning," Dr. Link said. Dr. Link shared his key characteristics of innovation: • Character counts • Take initiative (when it doubt, give it a try) • Good manners and high integrity • Build trust relationships • Hire great people, inspire, and empower them • Be a great communicator • Listen more than you talk • Hard work pays off • Take calculated risks • Don't take yourself too seriously "Remember, innovation is powered by courage, courage to fail, courage to try things," Dr. Link said. "[It is] powered by determination. … [And] if we're willing to let others share the credit for innovation, it's more powerful. So humility amplifies the impact of innovation." Other presentations Leading the other presentations in this Main Stage session was Sergio Canabrava, MD. He described the iterations of the double-flanged polypropylene technique for multiples uses in ophthalmology. Shin Yamane, MD, PhD, described the dou- ble-needle flanged scleral suture IOL fixation technique in 2016, taking home the grand prize at the ASCRS Film Festival that year. In 2017, Dr. Canabrava presented on the double-flanged technique for the first time with a transscleral bag fixation at the ASCRS Film Festival. Since 2019, he said many surgeons have used his technique with double-flanged polypropylene. Dr. Canabrava gave his five main princi- ples for this technique: 1) Mark 2 mm from the limbus, 2) make a long scleral tunnel, 3) hold the base of the Prolene with tension, 4) use the correct flange size, and 5) bury the knot. Next, Mark Lobanoff, MD, described striv- ing for perfection in LASIK and the impact of Phorcides software. He said that the software was created for topography-guided ablations that could correct aberrations on the cornea. "One of the things we recognized was that higher order aberrations matter to visual acuity," he said. companies in ophthalmology and helped create new market categories. Dr. Kelman, upon meeting Dr. Link in 1978, asked if Dr. Link would help him make an IOL. This would eventually lead to the Kelman Tri- pod lens in 1979. "Through the decades, not only did we have a lot of personal and professional interaction, but he welcomed me and my family into his family," Dr. Link said. Later in his presentation, he said that for innovation, the power of rela- tionships matters. Dr. Link shared a story about himself and Dr. Kelman. While on the golf course, they started talking about ideas. After the game, they took Dr. Kelman's helicopter to his Manhattan practice, and while on the walk there, they made a call to his patent attorney. After seeing a few patients in his office, he had a fax of a draft patent. He provided his edits, faxed it back, and returned to seeing patients. By the end of that same day, Dr. Kelman had a filed patent. "He had resources that were so responsive and knowledgeable around him. He didn't want to think about it and noodle on it. He took continued from page 30 Dr. Link speaks about his history and experience in the world of ophthalmic innovation, delivering the Charles D. Kelman, MD, Innovator's Lecture. Source: ASCRS

• Blank Page
• Blank Page (1)